Liver Cancer Diagnostics Market to Reach USD 18.4 Billion by 2035, Driven by Advanced Detection Technologies

The global liver cancer diagnostics market was valued at USD 9.6 billion in 2024 and is projected to grow steadily, reaching USD 18.4 billion by 2035. This expansion reflects the rising prevalence of liver cancer, increasing adoption of advanced diagnostic technologies, and raising awareness of early disease detection. Over the forecast period from 2025 to 2035, the market is anticipated to register a CAGR of 6.1%, supported by improvements in imaging, biomarker-based testing, and screening programs worldwide.

Strengthening healthcare facilities and the expansion of public health screening programs are significant drivers of the liver cancer diagnostics market. Enhanced laboratory networks and enhanced access to tertiary care centers in the form of public-private partnerships and strategic financial planning enhance diagnostic volumes and test uptake. Enhanced education of clinicians and guideline-based surveillance of high-risk groups boost referral volumes and market demand.

Your Key to Data-Driven Success: Explore In-Depth Data - Request Your Sample! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=61431

Supportive reimbursement models and the inclusion of diagnostic tests in national health benefit packages have helped check expenditures and facilitated easy adoption, hence forming the basis for consistent market growth. Capacity-building programs, including specialized training of pathologists and radiologists, raise the quality of diagnostics.

Market Segmentation

Segment

Categories

By Service Type

Laboratory Tests (AFP, LFTs), Imaging (CT, MRI, Ultrasound), Endoscopy, Biopsy

By Sourcing Type

In-house Diagnostics, Outsourced Diagnostic Services

By Application

Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Hepatoblastoma

By Industry Vertical

Hospitals & Diagnostic Centers, Pharmaceutical & CROs, Academic Research

By Region

North America, Europe, Asia-Pacific, Latin America, MEA

Regional Analysis

North America (Dominant Market)

North America continues to hold the largest market share (approx. 40%). This dominance is fueled by a robust reimbursement landscape, high awareness of liver screening, and the rapid adoption of AI-powered imaging systems. In 2025 alone, the U.S. expects over 42,000 new cases, necessitating a high volume of diagnostic procedures.

Asia-Pacific (Fastest Growing)

The Asia-Pacific region is poised for the highest CAGR.9 Driven by the high prevalence of Hepatitis B in countries like China and India, alongside improving healthcare infrastructure and government-led screening programs (e.g., India's NPCDCS), the region is becoming a global hub for diagnostic manufacturing and clinical trials.

Market Drivers and Challenges

Key Drivers

Rising Disease Prevalence: Increased cases of cirrhosis, obesity-linked fatty liver, and alcohol consumption (projected to hit 8.1 liters per capita by 2025).

Technological Innovation: The emergence of Liquid Biopsies and Next-Generation Sequencing (NGS) allows for detection via simple blood draws rather than painful tissue samples.

AI Integration: AI algorithms are reducing human error in detecting small tumors that might be missed by the naked eye on an MRI or CT scan.

Critical Challenges

High Costs: Advanced molecular and imaging tests remain prohibitively expensive in low-income regions, limiting market penetration.

Asymptomatic Nature: Early-stage liver cancer often shows no symptoms, leading to late-stage diagnoses where the market for curative diagnostics is smaller.

Lack of Universal Guidelines: Inconsistent screening protocols across different countries lead to variability in patient outcomes.

Market Trends & Future Outlook

Shift to Liquid Biopsies: Non-invasive monitoring of circulating tumor DNA (ctDNA) is expected to become the gold standard for high-risk patient surveillance by 2030.

Point-of-Care (PoC) Testing: Developing portable ultrasound and molecular devices for rural and remote areas to bridge the diagnostic gap.

Personalized Medicine: Using biomarkers (like AFP-L3 and DCP) to tailor specific diagnostic pathways based on a patient's genetic profile.

Multi-Omics Approach: Combining genomics and proteomics to increase the sensitivity of tests for early-stage HCC.

Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=61431<ype=S

Competitive Landscape

The market is characterized by high consolidation among top-tier medical technology firms. Key players are focusing on Mergers and Acquisitions (M&A) to integrate AI and molecular capabilities into their existing portfolios.

Key Market Players:

F. Hoffmann-La Roche AG
AdvaCare Pharma
Siemens Healthineers AG
QIAGEN
Bio-Rad Laboratories, Inc.
Agilent Technologies Inc.
Atlas Medical GmbH
Epigenomics AG
GE HealthCare
Koninklijke Philips N.V
CANON MEDICAL SYSTEMS CORPORATION
Samsung Medison Co., Ltd.
Hipro Biotechnology Co., Ltd.
Mursla Ltd. / Mursla Inc.
Exact Sciences Corporation
Helio Genomics

Recent Developments

In June 2025, Mursla Bio. Announced that the FDA had granted breakthrough device designation to the EvoLiver test for hepatocellular carcinoma (HCC) surveillance among high-risk cirrhosis patients. The EvoLiver test would separate organ-specific hepatocyte EVs from blood with enrichment such that fewer than 10 microRNAs and proteins would be quantitated as HCC biomarker signatures.

In April 2025, scientists at Wuhan Union Hospital, through the development of a new immunoPET tracer, 68Ga-aGPC3-scFv (XH06), were able to show that it could detect hepatocellular carcinoma (HCC) with high sensitivity and specificity, even in the case of tumours less than one centimetre in size. The first-in-class molecular imaging agent targeting glypican-3 (GPC3) is a potential bright diagnostic and staging instrument for HCC, a major contributor to the death of cancer patients worldwide.

Key Market Study Points

Dominant Segment: Laboratory tests currently hold the largest share (~40.5%) due to their cost-effectiveness.

End-User Lead: Hospitals remain the primary site for diagnosis due to integrated oncology departments.

Growth Hotspot: Non-invasive imaging and liquid biopsy segments will outpace traditional biopsy growth through 2035.

Frequently Asked Questions (FAQs)

What is the current size of the liver cancer diagnostics market?
The global liver cancer diagnostics market was valued at USD 9.6 billion in 2024.

How big is the liver cancer diagnostics market expected to be by 2035?
The market is projected to reach USD 18.4 billion by 2035.

What is the expected growth rate of the liver cancer diagnostics market?
The industry is anticipated to expand at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2035.

What factors are driving the growth of the liver cancer diagnostics market?
Key growth drivers include the rising prevalence of liver cancer, increasing awareness of early diagnosis, advancements in imaging and biomarker-based diagnostics, and expanding screening initiatives worldwide.

Which diagnostic methods are commonly used for liver cancer detection?
Common diagnostic methods include imaging techniques (ultrasound, CT scans, MRI), blood-based biomarker tests (such as AFP), and biopsy procedures.

Explore Latest Research Reports by Transparency Market Research:

Cell Free RNA Diagnostics Market - https://www.transparencymarketresearch.com/cell-free-rna-diagnostics-market.html

Gastric Cancer Diagnostics Market - https://www.transparencymarketresearch.com/gastric-cancer-diagnostics-market.html

Gene Fusion Testing Market - https://www.transparencymarketresearch.com/gene-fusion-testing-market.html

Specimen Collection Cards Market - https://www.transparencymarketresearch.com/specimen-collection-cards-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.